Enhanced Cytotoxic Activity of 6-Mercaptopurine-Loaded Solid Lipid Nanoparticles in Hepatic Cancer Treatment

Basit Öğe Kaydı
dc.authoridOltulu, Cagatay/0000-0002-6051-3479
dc.authoridErgin, Ahmet Dogan/0000-0002-9387-0085
dc.authorwosidOltulu, Cagatay/V-1823-2018
dc.authorwosidErgin, Ahmet Dogan/AAO-1876-2021
dc.contributor.authorErgin, Ahmet Dogan
dc.contributor.authorOltulu, Cagatay
dc.contributor.authorKoc, Buesra
dc.date.accessioned2024-06-12T11:15:24Z
dc.date.available2024-06-12T11:15:24Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstract6-Mercaptopurine (6-MCP) is an antiproliferative purine analog used in acute lymphoblastic leukemia, non-Hodgkin lymphoma, and inflammatory bowel disease (Crohn's disease, ulcerative colitis). Although 6-MCP has the great therapeutic potential for cancer and immunosuppressant-related diseases, 6-MCP is not readily soluble in water, presents a high first-pass effect, short half-life (0.5-1.5 h), and implies a low bioavailability (16%). On the contrary, solid lipid nanoparticles (SLNs) are prepared from solid lipids at room temperature and body temperature. In this study, SLNs were prepared w/o/w double emulsion-solvent evaporation method using Precirol ATO5 as matrix lipid. In the emulsion stabilization, surfactant (Tween 80) and polymeric stabilizer (polyvinyl alcohol [PVA]) were used. Two group formulations using Tween 80 and PVA were compared in terms of particle size, polydispersity index, zeta potential encapsulation efficiency%, and process yield%. Differential calorimetric analysis and release properties were examined for optimum formulation, and release kinetics were calculated. According to studies, sustained release was obtained with SLNs by the Korsmayer-Peppas kinetic model. The in vitro cytotoxicity studies were performed on the hepatocarcinoma (HEP3G) cell line. According to the results, successful SLN formulations were produced, and PVA was found best stabilizer. Optimum formulation exhibited significantly higher cytotoxic effects on HEP3G than on pure 6-MCP. These results demonstrated that solid lipid nanodrug delivery systems have great potential for formulation of 6-MCP.en_US
dc.description.sponsorshipTrakya University Scientific and Technological Research Council [2021/30]en_US
dc.description.sponsorshipThis study was supported by the Trakya University Scientific and Technological Research Council under grant 2021/30en_US
dc.identifier.doi10.1089/adt.2023.007
dc.identifier.endpage221en_US
dc.identifier.issn1540-658X
dc.identifier.issn1557-8127
dc.identifier.issue5en_US
dc.identifier.pmid37417972en_US
dc.identifier.scopus2-s2.0-85165223248en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage212en_US
dc.identifier.urihttps://doi.org/10.1089/adt.2023.007
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23917
dc.identifier.volume21en_US
dc.identifier.wosWOS:001023710900001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMary Ann Liebert, Incen_US
dc.relation.ispartofAssay And Drug Development Technologiesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSolid Lipid Nanoparticleen_US
dc.subject6-Mercaptopurineen_US
dc.subjectHepatic Canceren_US
dc.subjectToxicityen_US
dc.subjectCell Cultureen_US
dc.subjectFormulationen_US
dc.subjectPathwaysen_US
dc.subjectEmulsionen_US
dc.subjectDeliveryen_US
dc.titleEnhanced Cytotoxic Activity of 6-Mercaptopurine-Loaded Solid Lipid Nanoparticles in Hepatic Cancer Treatmenten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu